Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREVAIL: Phase 3 felzartamab in adults with IgA nephropathy
jRCT2031250155Phase 3Recruiting
- Sponsor
- Biogen
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of felzartamab in IgA nephropathy (IgAN) (4 cohorts), sponsored by Biogen. Primary endpoint: Percent change from baseline in proteinuria by UPCR. Started Sep 2025; status: recruiting.
02
Drugs
felzartamab
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on jRCT2031250155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250155.